Article: The use of oral antidiabetic agents in primary care.
2007 Volume 36, Issue 6, Page(s) 477–480
Abstract: Background: Guidelines and regulatory documents reflect the potential for chronic kidney disease to impact the efficacy and safety profiles of antidiabetic regimens. We describe the influence of impaired kidney function and its perception by ... ...
Abstract | Background: Guidelines and regulatory documents reflect the potential for chronic kidney disease to impact the efficacy and safety profiles of antidiabetic regimens. We describe the influence of impaired kidney function and its perception by practitioners on the pattern of antidiabetic use in Australian primary care. Methods: Antidiabetic agent prescribing was documented for 3893 patients with type 2 diabetes from the National Evaluation of the Frequency of Renal impairment cO-existing with Noninsulin dependent diabetes mellitus (NEFRON) study. Patients with and without impaired kidney function, identified by their practitioner or defined by an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m2, were systematically compared. Results: Most patients received metformin (63%) with sulphonylureas (45%), insulin (13%) and thiazolidinediones (7%) also widely used. Contrary to prescribing guidelines, use of metformin remained frequent (53%) and the proportional usage of sulphonylureas with active metabolites was unchanged in the 23.1% of patients with an eGFR below 60 mL/min/1.73 m2. Even where prescribers identified impaired kidney function in their patients, prescribing of antidiabetic agents was not significantly modified. Discussion: Chronic kidney disease is a common companion to type 2 diabetes in Australia. The move to automated eGFR reporting provides an important opportunity for practitioners to identify impaired kidney function and to improve their management of patients with type 2 diabetes. |
---|---|
MeSH term(s) | Aged ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Drug Utilization Review ; Female ; Glomerular Filtration Rate ; Guideline Adherence ; Humans ; Hypoglycemic Agents/administration & dosage ; Hypoglycemic Agents/therapeutic use ; Insulin/therapeutic use ; Kidney Failure, Chronic/complications ; Kidney Failure, Chronic/diagnosis ; Male ; Metformin/therapeutic use ; Pilot Projects ; Primary Health Care/standards |
Chemical Substances | Hypoglycemic Agents ; Insulin ; Metformin (9100L32L2N) |
Language | English |
Publishing date | 2007-06 |
Publishing country | Australia |
Document type | Journal Article |
ZDB-ID | 423718-3 |
ISSN | 0300-8495 |
ISSN | 0300-8495 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.B 2235: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
|||
Zs.MG 27: Show issues | ||||
Zs.MO 642: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.